Cytokinetics (CYTK) Announces Proposed Public Offering of Common Stock

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 million of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock in the offering will be sold by Cytokinetics.

J.P. Morgan, Goldman Sachs & Co. LLC and Morgan Stanley are acting as sole joint book-running managers for the offering.

You May Also Be Interested In

• Select Medical stockholders approve buyout by insider-led consortium
• Tempest Therapeutics (TPST) files for 2.43M share offering by selling stockholders
• Robo.ai Inc (AIIO) files for 22.34M share offering by selling stockholders